Wall Street analysts expect Opko Health Inc. (NASDAQ:OPK) to announce ($0.08) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Opko Health’s earnings. The lowest EPS estimate is ($0.10) and the highest is ($0.05). Opko Health reported earnings of ($0.04) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 100%. The company is expected to issue its next quarterly earnings report on Wednesday, March 7th.

On average, analysts expect that Opko Health will report full-year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.22). For the next financial year, analysts forecast that the business will post earnings of ($0.17) per share, with EPS estimates ranging from ($0.24) to ($0.06). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Opko Health.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The company had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. Opko Health’s revenue was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.03) earnings per share.

A number of research analysts have commented on the stock. Jefferies Group restated a “hold” rating and issued a $6.50 price objective (down from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Zacks Investment Research lowered shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Ladenburg Thalmann Financial Services restated a “buy” rating and issued a $16.00 price objective on shares of Opko Health in a research note on Monday, September 25th. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Saturday, September 23rd. Finally, J P Morgan Chase & Co lowered shares of Opko Health from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $12.00 to $7.00 in a research note on Thursday, September 14th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $13.97.

In related news, major shareholder Opko Health, Inc. acquired 655,738 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $3.05 per share, with a total value of $2,000,000.90. Following the completion of the acquisition, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Phillip Md Et Al Frost acquired 260,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The shares were bought at an average cost of $5.98 per share, for a total transaction of $1,554,800.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $18,352,326.98. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 1,052,238 shares of company stock worth $4,374,796. Company insiders own 40.19% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in OPK. Teachers Advisors LLC lifted its holdings in shares of Opko Health by 3.0% in the first quarter. Teachers Advisors LLC now owns 405,251 shares of the biotechnology company’s stock valued at $3,242,000 after purchasing an additional 11,782 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Opko Health by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,621,128 shares of the biotechnology company’s stock valued at $12,968,000 after purchasing an additional 31,225 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its holdings in shares of Opko Health by 0.3% in the second quarter. Public Employees Retirement Association of Colorado now owns 73,417 shares of the biotechnology company’s stock valued at $483,000 after purchasing an additional 216 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Opko Health by 10.8% in the second quarter. Janney Montgomery Scott LLC now owns 28,579 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 2,787 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Opko Health by 20.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 1,095,177 shares of the biotechnology company’s stock valued at $7,207,000 after purchasing an additional 189,438 shares in the last quarter. 22.91% of the stock is currently owned by hedge funds and other institutional investors.

Opko Health (NASDAQ OPK) opened at $5.08 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health has a one year low of $4.50 and a one year high of $12.15.

TRADEMARK VIOLATION WARNING: “Opko Health Inc. (OPK) Expected to Announce Earnings of -$0.08 Per Share” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/12/08/opko-health-inc-opk-expected-to-announce-earnings-of-0-08-per-share-2.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.